Formycin 5'-triphosphate, a fluorescent analog of ATP, as a substrate for adenylate cyclase. 1981

E F Rossomando, and J H Jahngen, and J F Eccleston

Formycin 5'-triphosphate (FoTP), a fluorescent analog of ATP, is shown to be a substrate for the membrane-bound adenylate cyclase activity [ATP pyrophosphate-lyase (cyclizing), EC 4.6.1.1] from rat osteosarcoma cells. The formation of the adenylate cyclase reaction product, 3',5'-cyclic formycin monophosphate (cFoMP), was followed by the conventional radioimmunoassay (RIA) procedure used to detect cAMP and by an assay procedure in which the reaction product was separated from the substrate by reverse-phase high-pressure liquid chromatography (HPLC) and the reaction product was detected by fluorometry. Because the HPLC--fluorometric procedure can determine the amount of cFoMP present in the reaction mixture within 6 min, the enzymatic conversion of FoTP to cFoMP can be followed directly during the course of a typical 15-min incubation. The amount of cFoMP detected by this procedure was found to be within 2% of the values obtained by the RIA. The rate of product formation with FoTP was similar to that observed with ATP and the activity of the enzyme was enhanced about 5-fold with guanyl-5'-yl imidodiphosphate when either ATP or FoTP was used as the substrate. Kinetic studies revealed values for the Vmax of 120 pmol/min per mg of protein and apparent Km values of 220 microM with both substrates. In addition to suggesting that the recognition of the substrate by the adenylate cyclase may not require a specific chemical structure of the 5-membered ring of the base or a unique configuration about either the glycosyl or the C(5')-C(4') bond, the results of this study are consistent with the idea that the cytotoxicity observed with the adenosine analog formycin may be the result of its metabolism to cFoMP. Furthermore, these studies indicate that the fluorescent analog FoTP can be used, in combination with HPLC, to provide an alternative, nonradioactive direct method for the assay of adenylate cyclase catalytic activity.

UI MeSH Term Description Entries
D009374 Neoplasms, Experimental Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms. Experimental Neoplasms,Experimental Neoplasm,Neoplasm, Experimental
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D002462 Cell Membrane The lipid- and protein-containing, selectively permeable membrane that surrounds the cytoplasm in prokaryotic and eukaryotic cells. Plasma Membrane,Cytoplasmic Membrane,Cell Membranes,Cytoplasmic Membranes,Membrane, Cell,Membrane, Cytoplasmic,Membrane, Plasma,Membranes, Cell,Membranes, Cytoplasmic,Membranes, Plasma,Plasma Membranes
D005573 Formycins Pyrazolopyrimidine ribonucleosides isolated from Nocardia interforma. They are antineoplastic antibiotics with cytostatic properties.
D000262 Adenylyl Cyclases Enzymes of the lyase class that catalyze the formation of CYCLIC AMP and pyrophosphate from ATP. Adenyl Cyclase,Adenylate Cyclase,3',5'-cyclic AMP Synthetase,Adenylyl Cyclase,3',5' cyclic AMP Synthetase,AMP Synthetase, 3',5'-cyclic,Cyclase, Adenyl,Cyclase, Adenylate,Cyclase, Adenylyl,Cyclases, Adenylyl,Synthetase, 3',5'-cyclic AMP
D000903 Antibiotics, Antineoplastic Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. Antineoplastic Antibiotics,Cytotoxic Antibiotics,Antibiotics, Cytotoxic
D012265 Ribonucleotides Nucleotides in which the purine or pyrimidine base is combined with ribose. (Dorland, 28th ed) Ribonucleoside Phosphates,Ribonucleotide,Phosphates, Ribonucleoside
D012516 Osteosarcoma A sarcoma originating in bone-forming cells, affecting the ends of long bones. It is the most common and most malignant of sarcomas of the bones, and occurs chiefly among 10- to 25-year-old youths. (From Stedman, 25th ed) Sarcoma, Osteogenic,Osteogenic Sarcoma,Osteosarcoma Tumor,Osteogenic Sarcomas,Osteosarcoma Tumors,Osteosarcomas,Sarcomas, Osteogenic,Tumor, Osteosarcoma,Tumors, Osteosarcoma
D013379 Substrate Specificity A characteristic feature of enzyme activity in relation to the kind of substrate on which the enzyme or catalytic molecule reacts. Specificities, Substrate,Specificity, Substrate,Substrate Specificities

Related Publications

E F Rossomando, and J H Jahngen, and J F Eccleston
October 1992, European journal of pharmacology,
E F Rossomando, and J H Jahngen, and J F Eccleston
October 1989, Archives of biochemistry and biophysics,
E F Rossomando, and J H Jahngen, and J F Eccleston
January 1978, Analytical biochemistry,
E F Rossomando, and J H Jahngen, and J F Eccleston
February 1986, Neurochemical research,
E F Rossomando, and J H Jahngen, and J F Eccleston
June 1977, Biochemical and biophysical research communications,
E F Rossomando, and J H Jahngen, and J F Eccleston
October 1977, Life sciences,
E F Rossomando, and J H Jahngen, and J F Eccleston
September 1984, FEBS letters,
E F Rossomando, and J H Jahngen, and J F Eccleston
June 1982, Analytical biochemistry,
E F Rossomando, and J H Jahngen, and J F Eccleston
October 1983, The Journal of pharmacy and pharmacology,
E F Rossomando, and J H Jahngen, and J F Eccleston
July 1979, Life sciences,
Copied contents to your clipboard!